Archived Monthly Oncology Tumor Boards: Diagnosis and Management of Marginal Zone Lymphomas
Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Updates in the Treatment of Lymphoma
This presentation will help guide nurses in the use of novel agents, the timing of those agents, and the treatment when a patient has progressed after first-line therapy. New agents will be discussed, including administration information, side effects, and helpful patient education information for nursing.
Category
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Toxicities of CAR T-Cell Therapy: Beyond CRS and Neurotoxicity
The information presented in this talk will address the long-term effects of CAR T-cell therapy, including HLH/MAS, B-cell aplasia, and prolonged cytopenias. Nurses will learn how to recognize signs/symptoms of these effects and how to manage them in order to educate patients and provide ideal care to patients undergoing CAR T-cell therapy.
Category
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Updates to the Management of Patients with Relapsed/Refractory Indolent B-Cell Lymphomas
Oncologists and hematologists need to maintain high awareness of the recently approved targeted therapies and the precise indications for their use so that these can be incorporated in routine clinical practice in the appropriate patient population.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Management of Indolent Non-Hodgkin Lymphomas
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of the novel treatments for indolent non-Hodgkin lymphomas.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Treatment for Relapsed/Refractory Mantle Cell Lymphoma
The selection of optimal second-line therapy for mantle cell lymphoma (MCL) depends on the age and fitness of the patients as well as the eligibility for transplant or CAR T-cell therapy. In the absence of standard management, patients with relapsed/refractory MCL should be referred for participation in prospective clinical trials investigating novel treatment regimens.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Educating clinicians about the recent clinical advances and the benefits/risks associated with the use of transplant and CAR T-cell therapy can help them to make informed clinical decisions for individual patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation